Olanzapine/Samidorphan in Young Adults With Schizophrenia, SchizophreniformDisorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study. Patients with early-phase schizophrenia or bipolar I disorder (BD-I) are at greater risk for antipsychotic-associated weight gain. This 12-week, randomized, double-blind study conducted between June 2017 and December 2021 evaluated weight effects of combination olanzapine and samidorphan (OLZ/SAM) versus olanzapine in early-phase illness. Young adults (16-39 years) with schizophrenia, schizophreniformdisorder, or BD-I, < 4 years since symptom onset, body mass index < 30 kg/m, and < 24 weeks' cumulative antipsychotic exposure were randomized to OLZ/SAM (5-20/10 mg/d) or olanzapine (5-20
Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniformdisorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) study. A post hoc analysis of the Disease Recovery Evaluation and Modification (DREaM) study was conducted to evaluate time to first major treatment failure (ie, arrest/incarceration or psychiatric hospitalization) in participants with recent-onset schizophrenia or schizophreniformdisorder treated with paliperidone palmitate (PP) versus oral antipsychotics (OAPs). DREaM was an open-label, delayed-start, randomized, multipart trial consisting of: Part I, 2-month oral run-in; Part II, 9-month disease progression phase (PP or OAP); and Part III, 9 months of additional treatment (PP/PP; OAP re-randomized
The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniformdisorder. We report primary results of the Disease Recovery Evaluation and Modification (DREaM) study, a randomized, open-label, delayed-start trial designed to compare the effectiveness of paliperidone palmitate (PP) versus oral antipsychotics (OAP) in delaying time to first treatment failure (TtFTF) in participants with recent-onset schizophrenia or schizophreniformdisorder. DREaM included: Part I, 2-month oral run-in; Part II, 9-month disease progression phase (PP or OAP); Part III, 9 months of additional treatment (PP/PP; OAP rerandomized: OAP/OAP or OAP/PP). PP/PP and OAP/OAP comprised the 18-month
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniformdisorder (OPTiMiSE): a three-phase switching study. No established treatment algorithm exists for patients with schizophrenia. Whether switching antipsychotics or early use of clozapine improves outcome in (first-episode) schizophrenia is unknown. This three-phase study was done in 27 centres, consisting of general hospitals and psychiatric specialty clinics, in 14 European countries and Israel. Patients aged 18-40 years who met criteria of the DSM-IV for schizophrenia, schizophreniformdisorder, or schizoaffective disorder were treated for 4 weeks with up to 800 mg/day amisulpride orally in an open-label design (phase 1). Patients who did not meet symptomatic remission
(“organic”) aetiologies.[2] Primary psychotic disorders include schizophrenia, delusional disorder, schizoaffective disorder, schizophreniformdisorder, and brief psychotic disorder. A psychotic syndrome may also accompany other psychiatric conditions such as major depressive disorder and bipolar disorder.[3] Patients with psychosis associated with psychiatric disorders present with a combination
(depressed or manic) are equally prominent. * Schizophreniformdisorder. * Brief psychotic disorder. * Drug-induced psychosis — substance-induced and usually remits within a month of cessation of use. * Persistent delusional disorder — where the most pervasive symptom is delusion. * A psychotic syndrome may also accompany other psychiatric conditions such as major depressive disorder and bipolar disorder
, or Veterans with schizophrenia.B. Guideline PopulationThe patient population of interest for this CPG is adults with schizophrenia,schizophrenia spectrum disorders, schizoaffective disorder, schizophreniformdisorder,or FEP being treated in any setting. It includes Veterans and Service members eligiblefor care in the VA or DoD health care delivery systems as well as those who receivecare from community
(schizo-phrenia, schizoaffective disorder, schizophreniformdisorder, brief psychotic disorder and substance-induced psychotic disor-der) and another medical condition. The DSM-5-TR also includes a category for unspecified catatonia (American Psychiatric Asso-ciation, 2013). The DSM-IV Handbook of Differential Diagnosis (First et al., 1995) provided a helpful hierarchy of diagnosis